Bubs Australia Ltd
Bubs Australia Boosts FY26 Outlook on Strong US Growth
Bubs Australia lifts FY26 outlook on robust US growth, guiding $120-125M revenue and $4-6M EBITDA as US revenue jumps 48% to $34.2M.
Market wrap: Australia ignores Wall Street record on faltering miners
The Australian share market once again ignored a rally on Wall Street to a fresh record high and closed down 0.3% thanks to a broad-based slump on Friday. It was yet another reminder of how the Australian bourse with its heavy concentration of miners and banks has disconnected from the Artificial Intelligence rally that is […]
Bubs Australia reports strong US sales and rebounding Chinese market
Organic infant formula manufacturer Bubs Australia (ASX: BUB) has reported continued strong performance of its product range in the US market. The company’s weekly scan revenue has exceeded US$1 million with over 24,000 tins sold, compared to US$750,000 in revenue for the previous quarter. It retained the position of the best-selling infant formula product on […]
Bubs Australia launches infant formula trial to secure the US market
Bubs Australia (ASX: BUB) has commenced nationwide enrolment for a growth monitoring study (GMS) in the US as part of its ongoing commitment to serving the North American market. The first infant was enrolled in late August and the company is actively enrolling more patients online and through 13 healthcare clinics across the country. The […]